Valion Bio touts CDMO Velocity Bioworks as Section 232 tariffs hit imports up to 100%

Valion Bio, Inc.

Velocity Bioworks is Valion's wholly owned CDMO in San Antonio, offering process development, analytical services and early-phase GMP drug substance manufacturing.
Microbial GMP manufacturing at scales up to 200 liters; GMP mammalian capabilities also maintained for biologics through early clinical development.
New Section 232 pharmaceutical framework imposes tariffs of up to 100% on certain imported patented drugs and ingredients, effective September 29, 2026.
Velocity supports Valion's lead candidate Entolimod, in development as a potential medical countermeasure for Acute Radiation Syndrome.
Interim CEO Dean Zikria said Valion welcomes partner discussions; no new contracts, customers or financial impact were disclosed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.